Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis

被引:35
作者
Angus, BJ
Smith, MD
Suputtamongkol, Y
Mattie, H
Walsh, AL
Wuthiekanun, V
Chaowagul, W
White, NJ
机构
[1] Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand
[2] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England
[3] Univ Leiden Hosp, Dept Infect Dis, NL-2300 RC Leiden, Netherlands
[4] Sappasitprasong Hosp, Dept Med, Ubon Ratchatani, Thailand
[5] Siriraj Hosp, Dept Med, Bangkok, Thailand
关键词
Burkholderia pseudomallei; ceftazidime; continuous infusion; melioidosis therapy; pharmacodynamics; pharmacokinetics;
D O I
10.1046/j.1365-2125.2000.00179.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Experimental studies have suggested that constant intravenous infusion would be preferable to conventional intermittent bolus administration of beta-lactam antibiotics for serious Gram-negative infections. Severe melioidosis (Burkholderia pseudomallei infection) carries a mortality of 40% despite treatment with high dose ceftazidime. The aim of this study was to measure the pharmacokinetic and pharmacodynamic effects of continuous infusion of ceftazidime vs intermittent bolus dosing in septicaemic melioidosis. Methods Patients with suspected septicaemic melioidosis were randomised to receive ceftazidime 40 mg kg(-1) 8 hourly by bolus injection or 4 mg kg(-1) h(-1) by constant infusion following a 12 mg kg(-1) priming dose to perform estimation of pharmacokinetic and pharmacodynamic parameters. Results Of the 34 patients studied 16 (59%) died. Twenty patients had cultures positive for B. pseudomallei of whom 12 (60%) died. The median MIC90 of B. pseudomallei was 2 mg 1(-1), giving a target concentration C-T, of 8 mg 1(-1). The median (range) estimated total apparent volume of distribution, systemic clearance and terminal elimination half-lives of ceftazidime were 0.368 (0.231-0.573) 1 kg(-1), 0.058 (0.005-0.159) 1 kg(-1) h(-1) and 7.74 (1.95-44.71) h, respectively. Clearance of ceftazidime and creatinine clearance were correlated closely (1 =0.71; P<0.001) and there was no evidence of si,significant nonrenal clearance. Conclusions Simulations based on these data and the ceftazidime sensitivity of the B. pseudomallei isolates indicated that administration by constant infusion would allow significant dose reduction and cost saving. With conventional 8 h intermittent dosing to patients with normal renal function,, plasma ceftazidime concentrations could fall below the target concentration but this would be unlikely with a constant infusion. Correction for renal failure which is common in these patients is Clearance = k * creatinine clearance where k=0.072. Calculation of a loading dose gives median (range) values of loading dose, DL of 3.7 mg kg(-1) (1.9-4.6) and infusion rate I = 0.46 mg kg h(-1) (0.04-1.3) (which equals 14.8 mg kg(-1) day(-1)). A nomogram for adjustment in renal failure is given.
引用
收藏
页码:445 / 452
页数:8
相关论文
共 44 条
[1]  
[Anonymous], 1986, LANCET, V2, P286
[2]   Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections [J].
Benko, AS ;
Cappelletty, DM ;
Kruse, JA ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :691-695
[3]   MELIOIDOSIS - A MAJOR CAUSE OF COMMUNITY-ACQUIRED SEPTICEMIA IN NORTHEASTERN THAILAND [J].
CHAOWAGUL, W ;
WHITE, NJ ;
DANCE, DAB ;
WATTANAGOON, Y ;
NAIGOWIT, P ;
DAVIS, TME ;
LOOAREESUWAN, S ;
PITAKWATCHARA, N .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (05) :890-899
[4]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[5]   Continuous infusion of ceftazidime with an elastomeric infusion device [J].
Couldry, R ;
Sanborn, M ;
Klutman, NE ;
Strayer, AH .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (02) :145-149
[6]   IDENTIFICATION OF PSEUDOMONAS-PSEUDOMALLEI IN CLINICAL-PRACTICE - USE OF SIMPLE SCREENING-TESTS AND API20NE [J].
DANCE, DAB ;
WUTHIEKANUN, V ;
NAIGOWIT, P ;
WHITE, NJ .
JOURNAL OF CLINICAL PATHOLOGY, 1989, 42 (06) :645-648
[7]   THE ANTIMICROBIAL SUSCEPTIBILITY OF PSEUDOMONAS-PSEUDOMALLEI - EMERGENCE OF RESISTANCE INVITRO AND DURING TREATMENT [J].
DANCE, DAB ;
WUTHIEKANUN, V ;
CHAOWAGUL, W ;
WHITE, NJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 24 (03) :295-309
[8]  
DEKINOWSKI JM, 1993, ANTIMICROB AGENTS CH, V37, P464
[9]   ROLE OF PHARMACOKINETICS IN THE OUTCOME OF INFECTIONS [J].
DRUSANO, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (03) :289-297
[10]  
ELTOUNY M, 1991, J ANTIMICROB CHEMOTH, V28, P95